Skip to main content
logo
Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.610
-0.170 (-3.56%)
At close: Sep 9, 2026, 4:00 PM EDT
4.750
+0.140 (3.04%)
Pre-market: Sep 10, 2026, 7:00 AM EDT

Immuneering Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.322.08
Revenue Growth
-----84.76%-10.02%
Gross Profit
----0.160.93
Operating Income
-63.47-59.38-64.07-58.41-51.74-33.89
Net Income
-57.28-56.02-61.04-53.47-50.51-33.54
Earnings Per Share
-0.98-1.27-2.04-1.88-1.91-2.46
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
182.67217.0136.1485.67105.52150.2
Total Debt
3.633.824.164.464.845.36
Net Cash (Debt)
179.04213.1931.9881.2100.68144.83
Net Cash Growth
700.90%566.60%-60.61%-19.35%-30.48%297.13%
Net Cash Per Share
3.064.841.072.863.8210.64

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-56.75-45.34-55-48.97-44.1-30.85
Capital Expenditures
-0.24-0.14-0.08-0.34-0.74-0.06
Free Cash Flow
-56.99-45.49-55.08-49.31-44.84-30.91
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----50.11%44.56%
Operating Margin
-----16325.77%-1629.17%
Pretax Margin
-----15937.29%-1627.11%
Profit Margin
-----15937.29%-1612.33%
FCF Margin
-----14148.44%-1486.17%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
----404.05204.62